ARTICLE | Emerging Company Profile
Nested: 3D mapping to hit multiple tumor mutations with one drug
Versant-founded newco emerged with $90 million in series A funds to advance two small molecule candidates into the clinic
October 6, 2022 10:32 AM UTC
Nested is mapping tumor mutations onto 3D protein structures to identify clusters of driver mutations that could be targeted with a single compound.
One-year-old Nested Therapeutics Inc. debuted Thursday with $125 million in total funding, including $35 million in seed funding from founding investor Versant Ventures and $90 million from a series A financing led by Goldman Sachs Asset Management, with participation from Foresite Capital, Avidity Partners, Cowen Healthcare Investments and Section 32...